

Appendices

Appendix 1: Legends for coronal sections of brain in Immunocytochemical investigations (Chapter 4 & 7).

Section 1

aca -Anterior commissure, anterior	LSt -Lateral septal stripe
Acb -Accumbens nucleus	LSV -Lateral septal nucleus, ventral
AI -Agranular insular cortex	LV -Lateral ventricle
cc -Corpus callosum	M1 -Primary motor cortex
cg -Cingulum	M2 -Secondary motor cortex
Cg1 -Cingulate cortex area 1	mfb -medial forebrain bundle
Cg2 -Cingulate cortex area 2	MPA -Medial preoptic area
CI -Clastrum	MS -medial septal nucleus
CPu -Caudate putamen	Pir -Piriform cortex
DEn -Dorsal endopiriform nucleus	rf -Rhinal fissure
ec -External capsule	S1 -Primary somatosensory cortex
GI -Granular insular cortex	S1FL -Somatosensory 1, forelimb reg
HDB -Nucleus horizontal limb diagonal band	S2 -Secondary somatosensory cortex
ICj -Islands of Calleja	SHi -Septohippocampal nucleus
LAcSh -Lateral accumbens shell	Tu -Olfactory tubercle
Ld -Lambdoid septal zone	VDB -Nucleus vertical limb diagonal band
lo -Lateral olfactory tract	VP -Ventral pallidum
LSD -Lateral septal nucleus, dorsal	ZL -Zona limitans
LSI -Lateral septal nucleus, intermediate	

Section 2

3V -Third ventricle	fr -fasciculus retroflexus
A13 -A13 dopamine cells	GrDG -Granular layer, dentate gyrus
ACo -Anterior cortical amygdaloid nucleus	hif -Hippocampal fissure
AHP -Anterior hypothalamic area, posterior	I -Intercalated nuclei amygdala
alv -Alveus	ic -Internal capsule
aot -Accessory optic tract	IMD -Intermediodorsal thalamic nucleus
Arc -Arcuate hypothalamic nucleus	IPAC -Interstit nucleus post limb anterior commissure
AStr -Amygdalostriatal transition area	LaDL -Lateral amygdaloid nucleus, dorsolateral
B -Basal nucleus of Meynert	LDDM -Laterodorsal thalamic nucleus, dorsomedial
BLA -Basolateral amygdaloid nucleus, anterior	LDVL -Laterodorsal thalamic nucleus, ventrolateral
BLV -Basolateral amygdaloid nucleus, ventral	LEnt -Lateral entorhinal cortex
BMA -Basomedial amygdaloid, anterior	LGP -Lateral globus pallidus
BSTIA -Bed nucleus stria terminalis, intraamygdaloid	LH -Lateral hypothalamic area
CA1 -CA1 field, hippocampus	LHb -Lateral habenular nucleus
CA2 -CA2 field, hippocampus	LMol -Lacunosum moleculare layer, hippocampus
CA3 -CA3 field, hippocampus	LV -Lateral ventricle
cc -corpus callosum	M1 -Primary motor cortex
CeC -Central amygdaloid nucleus, caps div	M2 -Secondary motor cortex
CeL -Central amygdaloid nucleus, lat div	MDC -Mediodorsal thalamic nucleus, central
CeMPV -Central amygdaloid nucleus, med posteroventral	MDL -Mediodorsal thalamic nucleus, lateral
cg -Cingulum	MDM -Mediodorsal thalamic nucleus, medial
CL -Central lateral thalamic nucleus	MePD -Medial amygdaloid nucleus, posterodorsal
CM -Central medial thalamic nucleus	MePV -Medial amygdaloid nucleus, posteroventral
CPu -Caudate putamen (striatum)	mfb -Medial forebrain bundle
CxA -Cortex-amygdala transition zone	MGP -Medial globus pallidus
D3V -Dorsal third ventricle	MHb -Medial habenular nucleus
DEn -Dorsal endopiriform nucleus	Mol -Molecular layer dentate gyrus
df -Dorsal fornix	mt -Mammillothalamic tract
DG -Dentate gyrus	ns -Nigrostriatal bundle
dhc -Dorsal hippocampal commissure	opt -Optic Tract
DM -Dorsomedial hypothalamic nucleus	Or -Oriens layer, hippocampus
ec -External capsule	PC -Paracentral thalamic nucleus
Ect -Ectorhinal cortex	Pe -Periventricular hypothalamic nucleus
f -Fornix	Pir -Piriform cortex
fi -Fimbria hippocampus	PLCo -Posterolateral cortical amygdaloid nucleus
	Po -Posterior thalamic nuclear group

PoDG-Polymorphic layer, dentate gyrus
PRh-Perirhinal cortex
PV-Paraventricular thalamic nucleus
Py-Pyramidal cell layer, hippocampus
Rad-Stratum radiatum, hippocampus
Re-Reuniens thalamic nucleus
rf-Rhinal fissure
Rh-Rhomboid thalamic nucleus
RSA-Retrosplenial agranular cortex
RSG-Retrosplenial granular cortex
Rt-Reticular thalamic nucleus
S1BF-Somatosensory 1, barrel field
S1FL-Somatosensory 1, forelimb reg
S1HL-Somatosensory 1, hindlimb reg
S2-Secondary somatosensory cortex
SI-Substantia innominata
SLu-Stratum luciderm, hippocampus
sm-Stria medullaris, thalamus

Section 3

3V-Third ventricle
AHiAL-Amygdalohippocampal area, anterolateral
alv-Alveus
APTD-Anterior pretectal nucleus, dorsal
ArcLP-Arcuate hypothalamic nucleus, lateroposterior
ArcMP-Arcuate hypothalamic nucleus, medioposterior
Au1-Primary auditory cortex
AuD-Auditory cortex, dorsal part
AuV-Auditory cortex, ventral part
BLP-Basolateral amygdaloid nucleus, posterior
BMP-Basomedial amygdaloid nucleus, posterior
CA1-CA1 field, hippocampus
CA2-CA2 field, hippocampus
CA3-CA3 field, hippocampus
cc-Corpus callosum
cg-Cingulum
cp-Cerebral peduncle, basal
CPu-Caudate putamen (striatum)
D3V-Dorsal Third ventricle
DEn-Dorsal endopiriform nucleus
df-Dorsal fornix
DG-Dentate Gyrus
dhc-Dorsal hippocampal commissure
DLG-Dorsal lateral geniculate nucleus
DTM-Dorsal tuberomammillary nucleus
ec-External capsule
Ect-Ectorhinal cortex
eml-External medullary lamina
f-Fornix
FC-Fasciola cinereum
FF-Fields of Forel
fi-Fimbria hippocampus
fr-Fasciculus retroflexus
Gem-Gemini hypothalamic nucleus
GrDG-Granular layer, dentate gyrus
hbc-Habenular commissure
hif-Hippocampal fissure
IGL-Intergeniculate leaf
IMA-Intramedullary thalamic area
La-Lateral amygdaloid nucleus
LaDL-Lateral amygdaloid nucleus, dorsolateral
LaVM-Lateral amygdaloid nucleus, ventromedial
LEnt-Lateral entorhinal cortex

SOR-Supraoptic decussation
st-Stria terminalis
Sub-Submedial thalamic nucleus
SubI-Subincertal nucleus
VEN-Ventral endopiriform nucleus
VL-Ventrolateral thalamic nucleus
VM-Ventromedial thalamic nucleus
VMHC-Ventromedial hypothalamic nucleus, central
VMHDM-Ventromedial hypothalamic nucleus, dorsomedial
VMHVL-Ventromedial hypothalamic nucleus, ventrolateral
VPL-Ventral posterolateral thalamic nucleus
VPM-Ventral posteromedial thalamic nucleus
VRe-Ventral reuniens thalamic nucleus
Xi-Xiphoid thalamic nucleus
ZI-Zona incerta

LH-Lateral hypothalamic area
LMol-Lacunosum moleculare layer, hippocampus
LPLR-Lateral posterior thalamic nucleus, laterorostral
LPMR-Lateroposterior thalamic nucleus, mediorostral
LV-Lateral ventricle
ME-Median eminence
MePD-Medial amygdaloid nucleus, posterodorsal
ml-Medial Lemniscus
Mol-Molecular layer dentate gyrus
mt-Mammillothalamic tract
ns-Nigrostriatal bundle
opt-Optic tract
Or-Oriens layer, hippocampus
pc-Posterior commissure
PF-Parafascicular thalamic nucleus
PH-Posterior hypothalamic area
Pir-Piriform cortex
PLCo-Posterolateral cortical amygdaloid nucleus
PMCo-Posteromedial cortical amygdaloid nucleus
PMV-Premammillary nucleus, ventral
Po-Posterior thalamic nuclear group
PoDG-Polymorphic layer, dentate gyrus
PPtA-Posterior parietal association area
PR-Prerubral field
PrC-Precommissural nucleus
PRh-Perirhinal cortex
PSTh-Parasubthalamic nucleus
pv-Periventricular fibre system
PVP-Paraventricular thalamic nucleus, posterior
Py-Pyramidal cell layer, hippocampus
Rad-Stratum radiatum, hippocampus
rf-Rhinal fissure
RSA-Retrosplenial agranular cortex
RSG-Retrosplenial granular cortex
S1-Primary somatosensory cortex
SCO-Subcommissural organ
scp-Superior cerebellar ped
SLu-Stratum lucidem, hippocampus
SMT-Submammillothalamic nucleus
sox-Supraoptic decussation
SPF-Subparafascicular thalamic nucleus
STh-Subthalamic nucleus
SubG-Subgeniculate nucleus

Te-Terete hypothalamic nucleus
VEn-Ventral endopiriform nucleus
VLGMC-Ventrolateral geniculate nucleus, magnocell
VLGPC-Ventrolateral geniculate nucleus, parvocell
VPL-Ventral posterolateral thalamic nucleus
VPM-Ventral posteromedial thalamic nucleus


VPPC-Ventral posteromedial thalamic nucleus parvicel
VTM-Ventral tuberomammillary nucleus
ZID-Zona incerta, dorsal
ZIV-Zona incerta, ventral

Section 4


AHiPM-Amygdalohippocampal area, posteromedial
alv-Alveus
APir-Amygdalopiriform transition area
APT-Anterior pretectal nucleus
Aq-Aqueduct of Silvius
Au1-Primary auditory cortex
AuD-Auditory cortex, dorsal part
AuV-Auditory cortex, ventral part
BLP-Basolateral amygdaloid nucleus, posterior
bsc-Brachium superior colliculus
CA1-CA1 field, hippocampus
CA3-CA3 field, hippocampus
cg-Cingulum
cp-Cerebral peduncle, basal
csc-Commissure, superior colliculus
DG-Dentate Gyrus
dhc-Dorsal hippocampal commissure
Dk-Nucleus of Darkschewitsch
DpG-Deep grey layer, superior colliculus
DpMe-Deep mesencephalic nucleus
DpWh-Deep white layer, superior colliculus
ec-External capsule
Ect-Ectorhinal cortex
EW-Edinger-Westphal nucleus
fr-Fasciculus retroflexus
GrDG-Granular layer, dentate gyrus
hif-Hippocampal fissure
IF-Interfascicula
IMLF-Interstitial nucleus, mlf
IMLFG-Interstitial nucleus, mlf, greater part
InG-Intermediate grey layer superior colliculus
InWh-Intermediate white layer superior colliculus
ipf-Interpeduncular fossa
LEnt-Lateral entorhinal cortex
LMol-Lacunosum moleculare layer, hippocampus
MA3-Medial accessory oculomotor nucleus
MGD-Medial geniculate nucleus, dorsal
MGV-Medial geniculate nucleus, ventral
ml-Medial lemniscus
ML-Medial mammillary nucleus, lateral
MM-Medial mammillary nucleus, medial
Mol-Molecular layer dentate gyrus
mp-Mammillary peduncle
MT-Medial terminal nucleus accessory optic tract
mtg-Mammillotegmental tract
MZMG-Marginal zone medial geniculate
Op-Optic nerve layer superior colliculus
Or-Oriens layer, hippocampus
PAG-Periaqueductal grey
PBP-Parabrachial pigmented nucleus
pc-Posterior commissure
PIL-Posterior intralaminar thalamic nucleus
PLi-Posterior limitans thalamic nucleus
pm-Principle mammillary tract
PMCo-Posteromedial cortical amygdaloid nucleus
PoDG-Polymorphic layer, dentate gyrus

PoT-Post thalamic nucleus group, triangular
PP-Peripeduncular nucleus
PPT-Posterior pretectal nucleus
PRh-Perirhinal cortex
Py-Pyramidal cells, hippocampus
Rad-Stratum radiatum, hippocampus
rf-Rhinal fissure
RLi-Rostral linear nucleus raphe
RPC-Red nucleus, parvocellular
RSA-Retrosplenial agranular cortex
RSG-Retrosplenial granular cortex
S-Subiculum
scp-Superior cerebellar ped
SG-Supragenulate thalamic nucleus
SLu-Stratum lucidum, hippocampus
SNC-Substantia nigra, compact
SNL-Substantia nigra, lateral
SNR-Substantia nigra, reticular
SuG-Superficial grey, superior colliculus
SuM-Supramammillary nucleus
V1B-Primary visual cortex, binoc
V1M-Primary visual cortex, monoc
V2L-Secondary visual cortex, lateral
V2ML-Secondary visual cortex, mediolateral
V2MM-Secondary visual cortex, mediomedial
VTA-Ventral tegmental area
VTRZ-Visual tegmental relay zone
Zo-Zonal layer superior colliculus


Appendix 2: Summary timeline of the R6/2 model



Appendix 3: Summary timeline of the R6/1 model



Appendix 4: Summary timeline of the HD94 model



Appendix 5: Summary timeline of the HD80 model



References

A

Adams CW Oligodendroglia in multiple sclerosis. *Nature* 1984; **309**: 518.

Alpár A, Ueberham U, Brückner MK, Seeger G, Arendt T, Gärtner U. Different dendrite and dendritic spine alterations in basal and apical arbors in mutant human amyloid precursor protein transgenic mice. *Brain Research* 2006; **1099**: 189-198.

Ambrose CM, Duyao MP, Barnes G, Bates GP, Lin CS, Srinidhi J *et al.* Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. *Somat Cell Mol Genet* 1994; **20**: 27-38.

Amrani M, Allen NJ, O'Shea J, Corbett J, Dunn MJ, Tadjkarimi S *et al.* Role of catalase and heat shock protein on recovery of cardiac endothelial and mechanical function after ischemia. *Cardioscience* 1993; **4**: 193-198.

Andringa G, Lam KY, Chegary M, Wang X, Chase TN, Bennett MC Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. *FASEB J* 2004; **18**: 932-934.

Arnold DL Magnetic resonance spectroscopy: imaging axonal damage in MS. *J Neuroimmunol* 1999; **98**: 2-6.

Aronin N, Cooper PE, Lorenz LJ, Bird ED, Sagar SM, Leeman SE *et al.* Somatostatin is increased in the basal ganglia in Huntington disease. *Ann Neurol* 1983; **13**: 519-526.

Asamoah A, Nandi KN, Prouty L, Thurmon TF, Chen HK A case of insertional translocation involving chromosomes 2 and 4. *Clin Genet* 1998; **53**: 142-146.

Azmitia EC. Neuronal instability: implications for Rett's syndrome. *Brain Dev.* 2001; **23**: S1-S10

B

Baba M, Osumi M, Scott SV, Klionsky D, Ohsumi Y Two distinct pathways for targeting proteins from the cytoplasm to the vacuole/lysosome. *J Cell Biol* 1997; **139**: 1687-1695.

Bachoud-Lévi AC, Gaura V, Brugières P, Lefaucheur JP, Boissé MF, Maison P *et al.* Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. *Lancet neurology* 2006; **5**: 303-309.

Baehrecke EH. Autophagy: dual roles in life and death? *Nat Rev Mol Cell Biol* 2005; **6**: 505-510.

Bates GP, Harper PS and Jones AL Eds. Huntington's Disease. Vol. 45, Oxford University Press: Oxford, UK., Third ed., 2002:558.

Battaglia A, Carey JC, Wright TJ. Wolf-Hirschhorn (4p-) syndrome. *Advances in pediatrics* 2001; **48**: 75-113.

Belichenko PV & Dahlstrom A. Studies on the 3-dimensional architecture of dendritic spines and varicosities in human cortex by confocal laser scanning microscopy and Lucifer Yellow microinjections. *J Neurosci Methods* 1995; **57**:55-61.

Bence NF, Sampat RM, Kopito RR Impairment of the ubiquitin-proteasome system by protein aggregation. *Science* 2001; **292**: 1552-1555.

Benn SC, Woolf CJ Adult neuron survival strategies--slamming on the brakes. *Nat Rev Neurosci* 2004; **5**: 686-700.

Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH *et al.* Global changes to the ubiquitin system in Huntington's disease. *Nature* 2007; **448**: 704-708.

Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M, Bates GP Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target. *Hum Mol Genet* 2006; **15**: 33-44.

Bird ED, Iversen LL Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia. *Brain* 1974; **97**: 457-472.

Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R *et al.* Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. *Nat Cell Biol* 2001; **3**: 1014-1019.

Bolam JP. In: Bolam JP, ed. *Experimental Neuroanatomy A Practical Approach*. Oxford: IRL Press at Oxford University Press, 1992:1-29.

Bonini NM A genetic model for human polyglutamine-repeat disease in *Drosophila melanogaster*. *Philos Trans R Soc Lond, B, Biol Sci* 1999; **354**: 1057-1060.

Brand S, Rakic P Genesis of the primate neostriatum: [3H]thymidine autoradiographic analysis of the time of neuron origin in the rhesus monkey. *Neuroscience* 1979; **4**: 767-778.

Braun BC, Glickman M, Kraft R, Dahlmann B, Kloetzel PM, Finley D *et al.* The base of the proteasome regulatory particle exhibits chaperone-like activity. *Nat Cell Biol* 1999; **1**: 221-226.

Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. *Am J Hum Genet* 1997; **60**: 1202-1210.

Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H *et al.* Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. *Cell* 1992; **69**: 385.

- Bu J, Akhtar N, Nishiyama A Transient expression of the NG2 proteoglycan by a subpopulation of activated macrophages in an excitotoxic hippocampal lesion. *Glia* 2001; **34**: 296-310.
- Busch A, Engemann S, Lurz R, Okazawa H, Lehrach H, Wanker EE Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease. *J Biol Chem* 2003; **278**: 41452-41461.
- Butterworth NJ, Williams L, Bullock JY, Love DR, Faull RL, Dragunow M Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. *Neuroscience* 1998; **87**: 49-53.
- Byers RK, Gilles FH, Fung C Huntington's disease in children. Neuropathologic study of four cases. *Neurology* 1973; **23**: 561-569.
- C**
- Cammarata S, Caponnetto C, Tabaton M Ubiquitin-reactive neurites in cerebral cortex of subjects with Huntington's chorea: a pathological correlate of dementia? *Neurosci Lett* 1993; **156**: 96-98.
- Camps C, Iranzo V, Bremnes RM, Sirera R Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer* 2006; **14**: 1173-1183.
- Campuzano V, Montermini L, Moltò MD, Pianese L, Cossée M, Cavalcanti F et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. *Science* 1996; **271**: 1423-1427.
- Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. *J Neurosci* 1999; **19**: 3248-3257.
- Castaigne P, Escourolle R, Gray MF [Huntington's chorea and cerebellar atrophy. Apropos of an anatomoclinical case]. *Rev Neurol (Paris)* 1976; **132**: 233-240.
- Cenci di Bello I, Dawson MR, Levine JM, Reynolds R Generation of oligodendroglial progenitors in acute inflammatory demyelinating lesions of the rat brain stem is associated with demyelination rather than inflammation. *J Neurocytol* 1999; **28**: 365-381.
- Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. *J Neurosci* 2000; **20**: 6404-6412.
- Chang CM, Yu YL, Fong KY, Wong MT, Chan YW, Ng TH et al. Huntington's disease in Hong Kong Chinese: epidemiology and clinical picture. *Clinical and experimental neurology* 1994; **31**: 43-51.
- Chen M, Singer L, Scharf A, von Mikecz A Nuclear polyglutamine-containing protein aggregates as active proteolytic centers. *J Cell Biol* 2008; **180**: 697-704.

Cheng HW, Rafols JA, Goshgarian HG, Anavi Y, Tong J, McNeill TH Differential spine loss and regrowth of striatal neurons following multiple forms of deafferentation: a Golgi study. *Experimental Neurology* 1997; **147**: 287-298.

Chevalier-Larsen ES, O'Brien CJ, Wang H, Jenkins SC, Holder L, Lieberman AP *et al.* Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. *J Neurosci* 2004; **24**: 4778-4786.

Choi JY, Ryu JH, Kim HS, Park SG, Bae KH, Kang S *et al.* Co-chaperone CHIP promotes aggregation of ataxin-1. *Mol Cell Neurosci* 2007; **34**: 69-79.

Christensen H, Pain RH Molten globule intermediates and protein folding. *Eur Biophys J* 1991; **19**: 221-229.

Chronister R, Dyken P, Fields PA, Maertens P. Cellular distribution of lesions in Batten disease. *Am. J. Med. Genet.* 1995; **57**: 191-195

Conlon I, Raff M Size control in animal development. *Cell* 1999; **96**: 235-244.

Cummings CJ, Reinstein E, Sun Y, Antalfy B, Jiang Y, Ciechanover A *et al.* Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. *Neuron* 1999; **24**: 879-892.

D

Davenport C, B. and Muncey E, B. *American Journal of Insanity* 1916; **73**, 175 .

Davies SW, Beardsall K, Turmaine M, DiFiglia M, Aronin N, Bates GP Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? *Lancet* 1998; **351**: 131-133.

Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA *et al.* Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. *Cell* 1997; **90**: 537-548.

Davies SW, Turmaine M, Cozens BA, Raza AS, Mahal A, Mangiarini L *et al.* From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease. *Philos Trans R Soc Lond, B, Biol Sci* 1999; **354**: 981-989.

Day M, Wang Z, Ding J, An X, Ingham C, Shering A *et al.* Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. *Nat Neurosci* 2006; **9**: 251-259.

de Almeida LP, Ross CA, Zala D, Aebischer P, Déglon N Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. *J Neurosci* 2002; **22**: 3473-3483.

- De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJ *et al*. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. *Nature* 1998; **392**: 394-397.
- de la Monte SM, Vonsattel JP, Richardson EP. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. *J Neuropathol Exp Neurol* 1988; **47**: 516-525.
- Dhananjayan SC, Ismail A, Nawaz Z. Ubiquitin and control of transcription. *Essays Biochem* 2005; **41**: 69-80.
- DiFiglia M. Excitotoxic injury of the neostriatum: a model for Huntington's disease. *Trends Neurosci* 1990; **13**: 286-289.
- DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C *et al*. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. *Neuron* 1995; **14**: 1075-1081.
- DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP *et al*. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. *Science* 1997; **277**: 1990-1993.
- Djousse L, Knowlton B, Cupples LA, Marder K, Shoulson I, Myers RH. Weight loss in early stage of Huntington's disease. *Neurology* 2002; **59**: 1325-1330.
- Dobson CM. Principles of protein folding, misfolding and aggregation. *Semin Cell Dev Biol* 2004; **15**: 3-16.
- Dragunow M, Faull RL, Lawlor P, Beilharz EJ, Singleton K, Walker EB *et al*. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. *Neuroreport* 1995; **6**: 1053-1057.
- Dunaevsky A, Tashiro A, Majewska A, Mason C, Yuste R. Developmental regulation of spine motility in the mammalian central nervous system. *Proc Natl Acad Sci USA* 1999; **96**: 13438-13443.
- Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M *et al*. Trinucleotide repeat length instability and age of onset in Huntington's disease. *Nat Genet* 1993; **4**: 387-392.
- Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, McNeil SM *et al*. Inactivation of the mouse Huntington's disease gene homolog Hdh. *Science* 1995; **269**: 407-410.
- Díaz-Hernández M, Hernández F, Martín-Aparicio E, Gómez-Ramos P, Morán MA, Castaño JG *et al*. Neuronal induction of the immunoproteasome in Huntington's disease. *J Neurosci* 2003; **23**: 11653-11661.
- Díaz-Hernández M, Moreno-Herrero F, Gómez-Ramos P, Morán MA, Ferrer I, Baró AM *et al*. Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. *J Neurosci* 2004; **24**: 9361-9371.

Díaz-Hernández M, Torres-Peraza J, Salvatori-Abarca A, Morán MA, Gómez-Ramos P, Alberch J *et al.* Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. *J Neurosci* 2005; **25**: 9773-9781.

F

Fernández V, Bravo H, Kuljis R, Fuentes I Autoradiographic study of the development of the neostriatum in the rabbit. *Brain Behav Evol* 1979; **16**: 113-128.

Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM *et al.* Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. *J Neurosci* 2002; **22**: 1592-1599.

Ferrante RJ, Beal MF, Kowall NW, Richardson EP, Martin JB Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. *Brain Res* 1987; **411**: 162-166.

Ferrante RJ, Gutekunst CA, Persichetti F, McNeil SM, Kowall NW, Gusella JF *et al.* Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. *J Neurosci* 1997; **17**: 3052-3063.

Ferrante RJ, Kowall NW, Cipolloni PB, Storey E, Beal MF Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. *Exp Neurol* 1993; **119**: 46-71.

Ferrante RJ, Kowall NW, Richardson EP Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. *J Neurosci* 1991; **11**: 3877-3887.

Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B *et al.* Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. *J Neurosci* 2003; **23**: 9418-9427.

Fiala JC, Spacek J, Harris KM Dendritic spine pathology: cause or consequence of neurological disorders? *Brain Res Brain Res Rev* 2002; **39**: 29-54.

Fischer M, Kaech S, Knutti D, Matus A Rapid actin-based plasticity in dendritic spines. *Neuron* 1998; **20**: 847-854.

Forno LS, DeLanney LE, Irwin I. & Langston JW. Electron microscopy of Lewy bodies in the amygdala-parahippocampal region. Comparison with inclusion bodies in the MPTP-treated squirrel monkey. *Adv Neurol* 1996; **69**: 217-228.

Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM *et al.* Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. *Proc Natl Acad Sci USA* 2000; **97**: 13877-13882.

Funai K, Parkington JD, Carambula S, Fielding RA Age-associated decrease in contraction-induced activation of downstream targets of Akt/mTor signaling in skeletal muscle. *Am J Physiol Regul Integr Comp Physiol* 2006; **290**: R1080-6.

G

Gajkowska B, Cholewiński M, Gniadecki R Structure of cytomatrix and nuclear matrix revealed by embedment-free electron microscopy. *Acta neurobiologiae experimentalis* 2000; **60**: 147-158.

Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, Mortimer AM et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. *J Neurol Neurosurg Psychiatr* 1998; **65**: 446-453.

Gerber HP, Seipel K, Georgiev O, Höfferer M, Hug M, Rusconi S et al. Transcriptional activation modulated by homopolymeric glutamine and proline stretches. *Science* 1994; **263**: 808-811.

Gerfen CR Indirect-pathway neurons lose their spines in Parkinson disease. *Nat Neurosci* 2006; **9**: 157-158.

Gibb R, Kolb BA method for vibratome sectioning of Golgi-Cox stained whole rat brain. *J Neurosci Methods* 1998; **79**: 1-4.

Gleckman AM, Jiang Z, Liu Y, Smith TW Neuronal and glial DNA fragmentation in Pick's disease. *Acta Neuropathologica* 1999; **98**: 55-61.

Glover JR, Lindquist S Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins. *Cell* 1998; **94**: 73-82.

Goldberg AL Protein degradation and protection against misfolded or damaged proteins. *Nature* 2003; **426**: 895-899.

Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. *Nat Genet* 1996; **13**: 442-449.

Goto S, Hirano A Synaptophysin expression in the striatum in Huntington's disease. *Acta Neuropathologica* 1990; **80**: 88-91.

Graveland GA, Williams RS, DiFiglia M Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. *Science* 1985; **227**: 770-773.

Greenamyre JT, Shoulson I We need something better, and we need it now: fetal striatal transplantation in Huntington's disease? *Neurology* 2002; **58**: 675-676.

Grossman AW, Aldridge GM, Weiler IJ, Greenough WT Local protein synthesis and spine morphogenesis: Fragile X syndrome and beyond. *J Neurosci* 2006; **26**: 7151-7155.

Grove VE, Quintanilla J, DeVaney GT Improvement of Huntington's disease with olanzapine and valproate. *N Engl J Med* 2000; **343**: 973-974.

Guidetti P, Charles V, Chen EY, Reddy PH, Kordower JH, Whetsell, WO, et al. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. *Exp. Neurol.* 2001; **169**:340-350.

Gusella JF, MacDonald ME Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. *Nat Rev Neurosci* 2000; **1**: 109-115.

Gusella JF, McNeil S, Persichetti F, Srinidhi J, Novelletto A, Bird E et al. Huntington's disease. *Cold Spring Harb Symp Quant Biol* 1996; **61**: 615-626.

Gusella JF, Tanzi RE, Anderson MA, Hobbs W, Gibbons K, Raschtchian R et al. DNA markers for nervous system diseases. *Science* 1984; **225**: 1320-1326.

Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE et al. A polymorphic DNA marker genetically linked to Huntington's disease. *Nature* 1983; **306**: 234-238.

Gutkunst CA, Levey AI, Heilman CJ, Whaley WL, Yi H, Nash NR et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. *Proc Natl Acad Sci USA* 1995; **92**: 8710-8714.

Gutkunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. *J Neurosci* 1999; **19**: 2522-2534.

H

Hackam AS, Singaraja R, Wellington CL, Metzler M, McCutcheon K, Zhang T et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. *J Cell Biol* 1998; **141**: 1097-1105.

Hackam AS, Singaraja R, Zhang T, Gan L, Hayden MR In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease. *Hum Mol Genet* 1999; **8**: 25-33.

Hagerman RJ, Hagerman PJ The fragile X premutation: into the phenotypic fold. *Curr Opin Genet Dev* 2002; **12**: 278-283.

Hall MN, Raff M and Thomas G Eds. Cell growth control of cell size. Vol. Monograph 42, John Inglis, 2004:652.

Hansson O, Nylandsted J, Castilho RF, Leist M, Jäättelä M, Brundin P Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. *Brain Research* 2003; **970**: 47-57.

- Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R *et al*. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. *Nature* 2006; **441**: 885-889.
- Harper PS, Houlihan GD, Jones AL, MacMillan JC, Morris MR, Quarrell OWJ, Scourfield J, Shaw DJ, Soldan J and Tyler A. Huntington's Disease. Vol. 3 I, W.B Saunders: London, Second ed., 1996:438.
- Hattori H, Takao T, Ito M, Nakano S, Okuno T, Mikawa H Cerebellum and brain stem atrophy in a child with Huntington's chorea. *Computerized radiology : official journal of the Computerized Tomography Society* 1984; **8**: 53-56.
- Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R *et al*. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. *Hum Mol Genet* 2004; **13**: 1389-1405.
- Hayden MR. Huntington's Chorea Springer: New York, 1981.
- Hedreen JC, Folstein SE Early loss of neostriatal striosome neurons in Huntington's disease. *J Neuropathol Exp Neurol* 1995; **54**: 105-120.
- Helmlinger D, Tora L, Devys D Transcriptional alterations and chromatin remodeling in polyglutamine diseases. *Trends Genet* 2006; **22**: 562-570.
- Henley SM, Frost C, MacManus DG, Warner TT, Fox NC, Tabrizi SJ Increased rate of whole-brain atrophy over 6 months in early Huntington disease. *Neurology* 2006; **67**: 694-696.
- Hickey MA, Chesselet MF Apoptosis in Huntington's disease. *Prog Neuropsychopharmacol Biol Psychiatry* 2003; **27**: 255-265.
- Hockly E, Cordery PM, Woodman B, Mahal A, van Dellen A, Blakemore C *et al*. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. *Ann Neurol* 2002; **51**: 235-242.
- Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R *et al*. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. *Neuron* 1999; **23**: 181-192.
- Hoffner G, Djian P Transglutaminase and diseases of the central nervous system. *Front Biosci* 2005; **10**: 3078-3092.
- Holmes SE, Hearn EO, Ross CA, Margolis RL SCA12: an unusual mutation leads to an unusual spinocerebellar ataxia. *Brain Res Bull* 2001; **56**: 397-403.
- Holmes SE, O'Hearn E, Rosenblatt A, Callahan C, Hwang HS, Ingersoll-Ashworth RG *et al*. A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2. *Nat Genet* 2001; **29**: 377-378.

The Huntington's Disease Collaborative Research Group (HDCRG). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell* 1993; **72**: 971-983.

Huntington G On chorea. George Huntington, M.D. *The Journal of neuropsychiatry and clinical neurosciences* 2003; **15**: 109-112.

Huynh DP, Del Bigio MR, Ho DH, Pulst SM Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2. *Ann Neurol* 1999; **45**: 232-241.

Huynh DP, Figueroa K, Hoang N, Pulst SM Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. *Nat Genet* 2000; **26**: 44-50.

I

Iannicola C, Moreno S, Oliverio S, Nardacci R, Ciofi-Luzzatto A, Piacentini M Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease. *J Neurochem* 2000; **75**: 830-839.

Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM *et al.* Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/ glutamine repeats. *Nat Genet* 1996; **14**: 285-291.

Irwin SA, Galvez R, Greenough WT Dendritic spine structural anomalies in fragile-X mental retardation syndrome. *Cereb Cortex* 2000; **10**: 1038-1044.

Irwin S, Idupulapati M, Gilbert M, Harris J, Chakravarti A, Rogers E *et al.* Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. *Am J Med Genet* 2002; **111**: 140-146.

Ishikawa K, Watanabe M, Yoshizawa K, Fujita T, Iwamoto H, Yoshizawa T *et al.* Clinical, neuropathological, and molecular study in two families with spinocerebellar ataxia type 6 (SCA6). *J Neurol Neurosurg Psychiatr* 1999; **67**: 86-89.

J

Jackson GR, Salecker I, Dong X, Yao X, Arnheim N, Faber PW *et al.* Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. *Neuron* 1998; **21**: 633-642.

Jackson M, Gentleman S, Lennox G, Ward L, Gray T, Randall K *et al.* The cortical neuritic pathology of Huntington's disease. *Neuropathol Appl Neurobiol* 1995; **21**: 18-26.

Jackson WS, Tallaksen-Greene SJ, Albin RL, Detloff PJ Nucleocytoplasmic transport signals affect the age at onset of abnormalities in knock-in mice expressing polyglutamine within an ectopic protein context. *Hum Mol Genet* 2003; **12**: 1621-1629.

Jana NR, Nukina N BAG-1 associates with the polyglutamine-expanded huntingtin aggregates. *Neurosci Lett* 2005; **378**: 171-175.

Jeitner TM, Bogdanov MB, Matson WR, Daikhin Y, Yudkoff M, Folk JE et al. N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. *J Neurochem* 2001; **79**: 1109-1112.

Jeste DV, Barban L, Parisi J Reduced Purkinje cell density in Huntington's disease. *Experimental Neurology* 1984; **85**: 78-86.

Johnson GV, LeShoure R Immunoblot analysis reveals that isopeptide antibodies do not specifically recognize the epsilon-(gamma-glutamyl)lysine bonds formed by transglutaminase activity. *J Neurosci Methods* 2004; **134**: 151-158.

Johnston JA, Ward CL, Kopito RR Aggresomes: a cellular response to misfolded proteins. *J Cell Biol* 1998; **143**: 1883-1898.

Jordan BA, Fernholz BD, Khatri L, Ziff EB Activity-dependent AIDA-1 nuclear signaling regulates nucleolar numbers and protein synthesis in neurons. *Nat Neurosci* 2007; **10**: 427-435.

K

Kahlem P, Green H, Djian P Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. *Mol Cell* 1998; **1**: 595-601.

Karpuj MV, Garren H, Slunt H, Price DL, Gusella J, Becher MW et al. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. *Proc Natl Acad Sci USA* 1999; **96**: 7388-7393.

Kaufmann WE, Moser HW Dendritic anomalies in disorders associated with mental retardation. *Cereb Cortex* 2000; **10**: 981-991.

Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. *Nat Genet* 1994; **8**: 221-228.

Kazemi-Esfarjani P, Benzer S Genetic suppression of polyglutamine toxicity in *Drosophila*. *Science* 2000; **287**: 1837-1840.

Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. *Proc Natl Acad Sci USA* 2002; **99**: 10671-10676.

Keene CD, Sonnen JA, Swanson PD, Kopyov O, Leverenz JB, Bird TD et al. Neural transplantation in Huntington disease: long-term grafts in two patients. *Neurology* 2007; **68**: 2093-2098.

- Kegel KB, Kim M, Sapp E, McIntyre C, Castaño JG, Aronin N *et al.* Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. *J Neurosci* 2000; **20**: 7268-7278.
- Keirstead HS, Levine JM, Blakemore WF Response of the oligodendrocyte progenitor cell population (defined by NG2 labelling) to demyelination of the adult spinal cord. *Glia* 1998; **22**: 161-170.
- Kennedy L, Shelbourne PF Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease? *Hum Mol Genet* 2000; **9**: 2539-2544.
- Kerr JF, Wyllie AH, Currie AR Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer* 1972; **26**: 239-257.
- Kihira T, Yoshida S, Uebayashi Y, Yase Y, Yoshimasu F Involvement of Onuf's nucleus in ALS. Demonstration of intraneuronal conglomerate inclusions and Bunina bodies. *J Neurol Sci* 1991; **104**: 119-128.
- Kim YJ, Yi Y, Sapp E, Wang Y, Cuiffo B, Kegel KB *et al.* Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. *Proc Natl Acad Sci USA* 2001; **98**: 12784-12789.
- Kimball SR, O'Malley JP, Anthony JC, Crozier SJ, Jefferson LS Assessment of biomarkers of protein anabolism in skeletal muscle during the life span of the rat: sarcopenia despite elevated protein synthesis. *Am J Physiol Endocrinol Metab* 2004; **287**: E772-80.
- Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF *et al.* Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. *J Neurophysiol* 2001; **86**: 2667-2677.
- Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, Clark HB *et al.* Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. *Cell* 1998; **95**: 41-53.
- Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. *J Neurochem* 2003; **86**: 267-272.
- Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, Endo K *et al.* Unstable expansion of CAG repeat in hereditary dentatorubral-pallidolusian atrophy (DRPLA). *Nat Genet* 1994; **6**: 9-13.
- Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I *et al.* Loss of autophagy in the central nervous system causes neurodegeneration in mice. *Nature* 2006; **441**: 880-884.

Koob MD, Moseley ML, Schut LJ, Benzow KA, Bird TD, Day JW *et al.* An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8). *Nat Genet* 1999; **21**: 379-384.

Kopito RR Aggresomes, inclusion bodies and protein aggregation. *Trends Cell Biol* 2000; **10**: 524-530.

Koshy BT, Zoghbi HY The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis. *Brain Pathol* 1997; **7**: 927-942.

Kowall NW, Quigley BJ, Krause JE, Lu F, Kosofsky BE, Ferrante RJ Substance P and substance P receptor histochemistry in human neurodegenerative diseases. *Regul Pept* 1993; **46**: 174-185.

Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J *et al.* A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. *N Engl J Med* 1994; **330**: 1401-1406.

Krucker T, Siggins GR, Halpain S Dynamic actin filaments are required for stable long-term potentiation (LTP) in area CA1 of the hippocampus. *Proc Natl Acad Sci USA* 2000; **97**: 6856-6861.

Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF *et al.* Huntington aggregates may not predict neuronal death in Huntington's disease. *Ann Neurol* 1999; **46**: 842-849.

Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T *et al.* The role of autophagy during the early neonatal starvation period. *Nature* 2004; **432**: 1032-1036.

Kussman A and Nothnagel CWH. In. Virchow-Hirsch's Jahrbuch fur. Berlin, 1872:175.

L

La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. *Nature* 1991; **352**: 77-79.

Lafarga M, Berciano MT, Pena E, Mayo I, Castaño JG, Bohmann D *et al.* Clastosome: a subtype of nuclear body enriched in 19S and 20S proteasomes, ubiquitin, and protein substrates of proteasome. *Mol Biol Cell* 2002; **13**: 2771-2782.

Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, Campbell M *et al.* Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. *J Neurosci* 2001; **21**: 9112-9123.

Lansbury PT Structural neurology: are seeds at the root of neuronal degeneration? *Neuron* 1997; **19**: 1151-1154.

Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. *FASEB J* 2004; **18**: 39-51.

Leigh RJ, Newman SA, Folstein SE, Lasker AG, Jensen BA Abnormal ocular motor control in Huntington's disease. *Neurology* 1983; **33**: 1268-1275.

Leist M, Jäättelä M Four deaths and a funeral: from caspases to alternative mechanisms. *Nat Rev Mol Cell Biol* 2001; **2**: 589-598.

Leontovich TA, Mukhina JK, Fedorov AA & Belichenko PV. Morphological study of the entorhinal cortex, hippocampal formation, and basal ganglia in Rett syndrome patients. *Neurobiol. Dis.* 1999; **6**: 77-91

Li H, Li SH, Yu ZX, Shelbourne P, Li XJ Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. *J Neurosci* 2001; **21**: 8473-8481.

Li Z, Karlovich CA, Fish MP, Scott MP, Myers RM A putative Drosophila homolog of the Huntington's disease gene. *Hum Mol Genet* 1999; **8**: 1807-1815.

Lieberman AR The axon reaction: a review of the principal features of perikaryal responses to axon injury. *Int Rev Neurobiol* 1971; **14**: 49-124.

Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. *Hum Mol Genet* 2001; **10**: 137-144.

Lindblad K, Savontaus ML, Stevanin G, Holmberg M, Digre K, Zander C et al. An expanded CAG repeat sequence in spinocerebellar ataxia type 7. *Genome Res* 1996; **6**: 965-971.

Lipford JR, Deshaies RJ Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation. *Nat Cell Biol* 2003; **5**: 845-850.

Luthi-Carter R, Strand AD, Peters NL, Solano SM, Hollingsworth ZR, Menon AS et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. *Hum Mol Genet* 2000; **9**: 1259-1271.

Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. *Hum Mol Genet* 2002; **11**: 1911-1926.

M

Ma L, Morton A, Nicholson L Microglia density decreases with age in a mouse model of Huntington's disease. *Glia* 2003; **43**: 274-280.

MacDonald ME Huntingtin: alive and well and working in middle management. *Sci STKE* 2003; **207**: pe48.

- Macdonald V, Halliday G Pyramidal cell loss in motor cortices in Huntington's disease. *Neurobiol Dis* 2002; **10**: 378-386.
- Macdonald V, Halliday GM, Trent RJ, McCusker EA Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington's disease. *Neuropathol Appl Neurobiol* 1997; **23**: 492-495.
- Mangiarini L, Sathasivam K, Mahal A, Mott R, Seller M, Bates GP Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. *Nat Genet* **15**: 197-200.
- Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. *Cell* 1996; **87**: 493-506.
- Marchand R, Lajoie L Histogenesis of the striopallidal system in the rat. Neurogenesis of its neurons. *Neuroscience* 1986; **17**: 573-590.
- Markham CH, Knox JW Observations on Huntington's Chorea in childhood. *J Pediatr* 1965; **67**: 46-57.
- Matsuura T, Yamagata T, Burgess DL, Rasmussen A, Grewal RP, Watase K et al. Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. *Nat Genet* 2000; **26**: 191-194.
- Mazarakis NK, Cybulska-Klosowicz A, Grote H, Pang T, van Dellen A, Kossut M et al. Deficits in experience-dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington's disease mice. *J Neurosci* 2005; **25**: 3059-3066.
- Mazzarello P. The Hidden structure, a scientific biography of Camillo Golgi. Oxford: Oxford University Press, 1996:85-86
- McNeil SM, Novelletto A, Srinidhi J, Barnes G, Kornbluth I, Altherr MR et al. Reduced penetrance of the Huntington's disease mutation. *Hum Mol Genet* 1997; **6**: 775-779.
- Melino G, Knight R, Nicotera P How many ways to die? How many different models of cell death? *Cell Death Differ* 2005; **12** Suppl 2: 1457-1462.
- Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. *J Comp Neurol* 2003; **465**: 11-26.
- Miller VM, Nelson RF, Gouvion CM, Williams A, Rodriguez-Lebron E, Harper SQ et al. CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. *J Neurosci* 2005; **25**: 9152-9161.
- Mitchison HM, Bernard DJ, Greene ND, Cooper JD, Junaid MA, Pullarkat RK et al. Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected]. *Neurobiol Dis* 1999; **6**: 321-334.

- Mitchison HM, Lim MJ, Cooper JD Selectivity and types of cell death in the neuronal ceroid lipofuscinoses. *Brain Pathol* 2004; **14**: 86-96.
- Montagne J, Stewart MJ, Stocker H, Hafen E, Kozma SC, Thomas G Drosophila S6 kinase: a regulator of cell size. *Science* 1999; **285**: 2126-2129.
- Montel V, Gardrat F, Azanza JL, Raymond J 20S proteasome, hsp90, p97 fusion protein, PA28 activator copurifying oligomers and ATPase activities. *Biochem Mol Biol Int* 1999; **47**: 465-472.
- Montel V, Gardrat F, Azanza JL, Raymond J Heat-shock protein 90: intrinsic peptidase activity and in vitro long-term self-processing. *Life Sci* 2000; **67**: 1585-1600.
- Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML Dendrite and dendritic spine alterations in Alzheimer models. *J Neurocytol* 2004; **33**: 377-387.
- Morales LM, Estévez J, Suárez H, Villalobos R, Chacín de Bonilla L, Bonilla E Nutritional evaluation of Huntington disease patients. *Am J Clin Nutr* 1989; **50**: 145-150.
- Mortimore GE, Pösö AR The lysosomal pathway of intracellular proteolysis in liver: regulation by amino acids. *Adv Enzyme Regul* 1986; **25**: 257-276.
- Morton AJ, Lagan MA, Skepper JN, Dunnett SB Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation. *J Neurocytol* 2000; **29**: 679-702.
- Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, Bates GP et al. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. *J Neurosci* 2000; **20**: 5115-5123.
- Myers RH, Marans SK and MacDonald ME. In: Wells RD and Warren ST, eds. Genetic instabilities and hereditary neurological diseases Academic Press, 1998:301-323.
- Myers RH, Vonsattel JP, Paskevich PA, Kiely DK, Stevens TJ, Cupples LA et al. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. *J Neuropathol Exp Neurol* 1991; **50**: 729-742.
- Myers RH, MacDonald ME, Koroshetz WJ, Duyao MP, Ambrose CM, Taylor SA et al. De novo expansion of a (CAG)_n repeat in sporadic Huntington's disease. *Nat Genet* 1993; **5**: 168-173.
- N**
- Nagata E, Sawa A, Ross CA, Snyder SH Autophagosome-like vacuole formation in Huntington's disease lymphoblasts. *Neuroreport* 2004; **15**: 1325-1328.
- Nakamura K, Jeong SY, Uchihara T, Anno M, Nagashima K, Nagashima T et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. *Hum Mol Genet* 2001; **10**: 1441-1448.

Nakashima K, Watanabe Y, Kusumi M, Nanba E, Maeoka Y, Nakagawa M et al. Epidemiological and genetic studies of Huntington's disease in the San-in area of Japan. *Neuroepidemiology* 1996; **15**: 126-131.

Nance MA, Myers RH Juvenile onset Huntington's disease--clinical and research perspectives. *Mental retardation and developmental disabilities research reviews* 2001; **7**: 153-157.

Nance MA, Mathias-Hagen V, Breningstall G, Wick MJ, McGlennen RC Analysis of a very large trinucleotide repeat in a patient with juvenile Huntington's disease. *Neurology* 1999; **52**: 392-394.

Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. *Cell* 1995; **81**: 811-823.

Nishiyama A, Chang A, Trapp BD NG2+ glial cells: a novel glial cell population in the adult brain. *J Neuropathol Exp Neurol* 1999; **58**: 1113-1124.

O

Oberlé I, Vincent A, Abbadi N, Rousseau F, Hupkes PE, Hors-Cayla MC et al. New polymorphism and a new chromosome breakpoint establish the physical and genetic mapping of DXS369 in the DXS98-FRAXA interval. *Am J Med Genet* 1991; **38**: 336-342.

Ohanna M, Sobering A, Lapointe T, Lorenzo L, Praud C, Petroulakis E et al. Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. *Nat Cell Biol* 2005; **7**: 286-294.

Olney JW Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. *Science* 1969; **164**: 719-721.

Olney JW, Adamo NJ, Ratner A Monosodium glutamate effects. *Science* 1971; **172**: 294.

Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. *Nature* 1999; **399**: 263-267.

Orlowski M, Wilk S Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. *Arch Biochem Biophys* 2000; **383**: 1-16.

Orr HT, Zoghbi HY Reversing neurodegeneration: a promise unfolds. *Cell* 2000; **101**: 1-4.

Orr HT, Chung MY, Banfi S, Kwiatkowski TJ, Servadio A, Beaudet AL et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. *Nat Genet* 1993; **4**: 221-226.

P

- Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. *Nat Neurosci* 2002; **5**: 731-736.
- Papp MI, Lantos PL The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. *Brain* 1994; **117**: 235-243.
- Papp MI, Kahn JE, Lantos PL Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). *J Neurol Sci* 1989; **94**: 79-100.
- Paradiso S, Turner BM, Paulsen JS, Jorge R, BolesPonto LL et al. Neural bases of dysphoria in early Huntington's disease. *Psychiatry Res.* 2008; **162**:73-87.
- Park M, Salgado JM, Ostroff L, Helton TD, Robinson CG, Harris KM et al. Plasticity-induced growth of dendritic spines by exocytic trafficking from recycling endosomes. *Neuron* 2006; **52**: 817-830.
- Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC et al. Brain structure in preclinical Huntington's disease. *Biol Psychiatry* 2006; **59**: 57-63.
- Perez MK, Paulson HL, Pendse SJ, Saionz SJ, Bonini NM, Pittman RN Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. *J Cell Biol* 1998; **143**: 1457-1470.
- Perutz M Polar zippers: their role in human disease. *Protein Sci* 1994; **3**: 1629-1637.
- Perutz MF Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. *Curr Opin Struct Biol* 1996; **6**: 848-858.
- Perutz MF, Johnson T, Suzuki M, Finch JT Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. *Proc Natl Acad Sci USA* 1994; **91**: 5355-5358.
- Peters MF, Nucifora FC, Kushi J, Seaman HC, Cooper JK, Herring WJ et al. Nuclear targeting of mutant Huntingtin increases toxicity. *Mol Cell Neurosci* 1999; **14**: 121-128.
- Pflanz S, Besson JA, Ebmeier KP, Simpson S The clinical manifestation of mental disorder in Huntington's disease: a retrospective case record study of disease progression. *Acta psychiatrica Scandinavica* 1991; **83**: 53-60.
- Portera-Cailliau C, Hedreen JC, Price DL, Koliatsos VE Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. *J Neurosci* 1995; **15**: 3775-3787.
- Pratley RE, Salbe AD, Ravussin E, Caviness JN Higher sedentary energy expenditure in patients with Huntington's disease. *Ann Neurol* 2000; **47**: 64-70.

- Ptitsyn OB How does protein synthesis give rise to the 3D-structure? *FEBS Lett* 1991; **285**: 176-181.
- Purpura DP, Bodick N, Suzuki K, Rapin I, Wurzelmann S Microtubule disarray in cortical dendrites and neurobehavioral failure. I. Golgi and electron microscopic studies. *Brain Research* 1982; **281**: 287-297.
- R**
- Ranen NG, Stine OC, Abbott MH, Sherr M, Codori AM, Franz ML *et al.* Anticipation and instability of IT-15 (CAG)_n repeats in parent-offspring pairs with Huntington disease. *Am J Hum Genet* 1995; **57**: 593-602.
- Rasmussen A, Macias R, Yescas P, Ochoa A, Davila G, Alonso E Huntington disease in children: genotype-phenotype correlation. *Neuropediatrics* 2000; **31**: 190-194.
- Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG *et al.* Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. *Nat Genet* 2004; **36**: 585-595.
- Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell WO *et al.* Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. *Nat Genet* 1998; **20**: 198-202.
- Ridet JL, Malhotra SK, Privat A, Gage FH Reactive astrocytes: cellular and molecular cues to biological function. *Trends Neurosci* 1997; **20**: 570-577.
- Rockel T, von Mikecz A Proteasome-dependent processing of nuclear proteins is correlated with their subnuclear localization. *Journal of Structural Biology* 2002; **140**: 189-199.
- Rockel TD, Stuhlmann D, von Mikecz A Proteasomes degrade proteins in focal subdomains of the human cell nucleus. *J Cell Sci* 2005; **118**: 5231-5242.
- Rodda RA Cerebellar atrophy in Huntington's disease. *J Neurol Sci* 1981; **50**: 147-157.
- Roizin L, Stellar S, Willson N, Whittier J, Liu JC Electron microscope and enzyme studies in cerebral biopsies of Huntington's chorea. *Transactions of the American Neurological Association* 1974; **99**: 240-243.
- Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN *et al.* Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. *Nat Cell Biol* 2001; **3**: 1009-1013.
- Roos RA, Bots GT Nuclear membrane indentations in Huntington's chorea. *J Neurol Sci* 1983; **61**: 37-47.
- Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. *Neurology* 2005; **65**: 745-747.

Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. *Neurology* 2002; **58**: 695-701.

Ross CA, Poirier MA Protein aggregation and neurodegenerative disease. *Nat Med* 2004; **10** Suppl: S10-7.

Rubinsztein DC, Leggo J, Coles R, Almqvist E, Biancalana V, Cassiman JJ et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. *Am J Hum Genet* 1996; **59**: 16-22.

S

Sakai K, Yamada M, Sato T, Yamada M, Tsuji S, Takahashi H Neuronal atrophy and synaptic alteration in a mouse model of dentatorubral-pallidolusian atrophy. *Brain* 2006; **129**: 2353-2362.

Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F et al. Formation of polyglutamine inclusions in non-CNS tissue. *Hum Mol Genet* 1999; **8**: 813-822.

Satyal SH, Schmidt E, Kitagawa K, Sondheimer N, Lindquist S, Kramer JM et al. Polyglutamine aggregates alter protein folding homeostasis in *Caenorhabditis elegans*. *Proc Natl Acad Sci USA* 2000; **97**: 5750-5755.

Saudou F, Finkbeiner S, Devys D, Greenberg ME Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. *Cell* 1998; **95**: 55-66.

Sawhani V, Gupta RK, Singh MK, Kohli A MRI demonstration of Wallerian degeneration in various intracranial lesions and its clinical implications. *J Neurol Sci* 1997; **146**: 103-108.

Scharf A, Rockel TD, von Mikecz A Localization of proteasomes and proteasomal proteolysis in the mammalian interphase cell nucleus by systematic application of immunocytochemistry. *Histochem Cell Biol* 2007; **127**: 591-601.

Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. *Cell* 1997; **90**: 549-558.

Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. *Proc Natl Acad Sci USA* 1999; **96**: 4604-4609.

Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuc JA et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. *Hum Mol Genet* 1999; **8**: 397-407.

- Schubert U, Antón LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. *Nature* 2000; **404**: 770-774.
- Senut MC, Suhr ST, Kaspar B, Gage FH Intraneuronal aggregate formation and cell death after viral expression of expanded polyglutamine tracts in the adult rat brain. *J Neurosci* 2000; **20**: 219-229.
- Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. *Proc Natl Acad Sci USA* 2000; **97**: 4897-4902.
- Sharp AH, Loev SJ, Schilling G, Li SH, Li XJ, Bao J *et al.* Widespread expression of Huntington's disease gene (IT15) protein product. *Neuron* 1995; **14**: 1065-1074.
- Shelbourne PF, Killeen N, Hevner RF, Johnston HM, Tecott L, Lewandoski M *et al.* A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. *Hum Mol Genet* 1999; **8**: 763-774.
- Sherman MY, Goldberg AL Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. *Neuron* 2001; **29**: 15-32.
- Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC Disruption of the p70 (s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. *EMBO J* 1998; **17**: 6649-6659.
- Sholl DA. Dendritic organization in the neurons of the visual and motor cortices of the cat. *J Anat* 1953; **87**: 387-406.
- Shoshan Y, Nishiyama A, Chang A, Mörk S, Barnett GH, Cowell JK *et al.* Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. *Proc Natl Acad Sci USA* 1999; **96**: 10361-10366.
- Sieradzan KA, Mehan AO, Jones L, Wanker EE, Nukina N, Mann DM Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. *Exp Neurol* 1999; **156**: 92-99.
- Snow WM, Hartle K, Ivanko TL. Altered morphology of motor cortex neurons in the VPA rat model of autism. *Dev. Psychobiol.* 2008; **50**:633-639.
- Sotrel A, Williams RS, Kaufmann WE, Myers RH Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington's disease: a quantitative Golgi study. *Neurology* 1993; **43**: 2088-2096.
- Spargo E, Everall IP, Lantos PL Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. *J Neurol Neurosurg Psychiatr* 1993; **56**: 487-491.
- Spector DL Nuclear domains. *J Cell Sci* 2001; **114**: 2891-2893.

Spillantini MG, Crowther, RA, Jakes R, Hasegawa M, Goedert M. α -Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. *Proc Natl Acad Sci USA* 1998; **95**: 6469-6473.

Spires TL, Grote HE, Garry S, Cordery PM, van Dellen A, Blakemore C *et al*. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. *Eur J Neurosci* 2004a; **19**: 2799-2807.

Spires TL, Grote HE, Varshney NK, Cordery PM, van Dellen A, Blakemore C *et al*. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. *J Neurosci* 2004b; **24**: 2270-2276.

Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N *et al*. SUMO modification of Huntingtin and Huntington's disease pathology. *Science* 2004; **304**: 100-104.

Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL *et al*. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in *Drosophila*. *Nature* 2001; **413**: 739-743.

Stephens B, Mueller AJ, Shering AF, Hood SH, Taggart P, Arbuthnott GW *et al*. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. *Neuroscience* 2005; **132**: 741-754.

Strickland E, Hakala K, Thomas PJ, DeMartino GN Recognition of misfolding proteins by PA700, the regulatory subcomplex of the 26 S proteasome. *J Biol Chem* 2000; **275**: 5565-5572.

Suhr ST, Senut MC, Whitelegge JP, Faull KF, Cuizon DB, Gage FH Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. *J Cell Biol* 2001; **153**: 283-294.

Sun Y, Savanenin A, Reddy PH, Liu YF Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. *J Biol Chem* 2001; **276**: 24713-24718.

Sánchez A, Castellví-Bel S, Milà M, Genis D, Calopa M, Jiménez D *et al*. Huntington's disease: confirmation of diagnosis and presymptomatic testing in Spanish families by genetic analysis. *J Neurol Neurosurg Psychiatr* 1996; **61**: 625-627.

T

Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, Fox RR *et al*. FVB/N: An inbred mouse strain preferable for transgenic analyses. *PNAS* 1991; **88**: 2065-2069.

Telenius H, Kremer HP, Theilmann J, Andrew SE, Almqvist E, Anvret M *et al*. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)_n repeat length is the sex of the affected parent. *Hum Mol Genet* 1993; **2**: 1535-1540.

Tellez-Nagel I, Johnson AB, Terry RD Studies on brain biopsies of patients with Huntington's chorea. *J Neuropathol Exp Neurol* 1974; **33**: 308-332.

Thomas DR Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. *Clinical nutrition (Edinburgh, Scotland)* 2007; **26**: 389-399.

Thomas EA Striatal specificity of gene expression dysregulation in Huntington's disease. *J Neurosci Res* 2006; **84**: 1151-1164.

Thomas LB, Gates DJ, Richfield EK, O'Brien TF, Schweitzer JB, Steindler DA DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. *Experimental Neurology* 1995; **133**: 265-272.

Tisdale MJ The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. *The journal of supportive oncology* 2005; **3**: 209-217.

Trejo A, Boll MC, Alonso ME, Ochoa A, Velásquez L Use of oral nutritional supplements in patients with Huntington's disease. *Nutrition (Burbank, Los Angeles County, Calif)* 2005; **21**: 889-894.

Trejo A, Tarrats RM, Alonso ME, Boll MC, Ochoa A, Velásquez L Assessment of the nutrition status of patients with Huntington's disease. *Nutrition (Burbank, Los Angeles County, Calif)* 2004; **20**: 192-196.

Trottier Y, Biancalana V, Mandel JL Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. *J Med Genet* 1994; **31**: 377-382.

Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. *Proc Natl Acad Sci USA* 2000; **97**: 8093-8097.

Turner GC, Varshavsky A Detecting and measuring cotranslational protein degradation in vivo. *Science* 2000; **289**: 2117-2120.

U

Usdin MT, Shelbourne PF, Myers RM, Madison DV Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. *Hum Mol Genet* 1999; **8**: 839-846.

V

van Dellen A, Cordery PM, Spires TL, Blakemore C, Hannan AJ Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease. *BMC neuroscience* 2008; **9**: 34.

van Dellen A, Welch J, Dixon RM, Cordery P, York D, Styles P et al. N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. *Neuroreport* 2000; **11**: 3751-3757.

- van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR et al. Body weight is modulated by levels of full-length huntingtin. *Hum Mol Genet* 2006; **15**: 1513-1523.
- Vis JC, Schipper E, de Boer-van Huizen RT, Verbeek M, de Waal RM, Wesseling P et al. Expression pattern of apoptosis-related markers in Huntington's disease. *Acta Neuropathologica* 2005; **109**: 321-328.
- von Mikecz A The nuclear ubiquitin-proteasome system. *J Cell Sci* 2006; **119**: 1977-1984.
- Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Neuropathological classification of Huntington's disease. *J Neuropathol Exp Neurol* 1985; **44**: 559-577.
- W**
- Wanderer J, Morton AJ Differential morphology and composition of inclusions in the R6/2 mouse and PC12 cell models of Huntington's disease. *Histochem Cell Biol* 2007; **127**: 473-484.
- Wang G, Mitsui K, Kotliarova S, Yamashita A, Nagao Y, Tokuhiro S et al. Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. *Neuroreport* 1999; **10**: 2435-2438.
- Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. *J Biol Chem* 2000; **275**: 19831-19838.
- Westphal CFO. *Arch Psychiatrie Nervenkr* 1883; **14**, 87-95 & 767-773 .
- Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. *Proc Natl Acad Sci USA* 2004; **101**: 3498-3503.
- Wheeler VC, White JK, Gutekunst CA, Vrbancac V, Weaver M, Li XJ et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. *Hum Mol Genet* 2000; **9**: 503-513.
- Whetsell WO Current concepts of excitotoxicity. *J Neuropathol Exp Neurol* 1996; **55**: 1-13.
- Wolf RC, Vasic N, Schonfeldt-Leuona C, Ecker D, Landwehrmeyer GB. Cortical dysfunction in patients with Huntington's disease during working memory performance. *Hum. Brain Mapp.* 2009; **30**: 327-339.
- Wood BE, Kim KK, Harpold GJ Psychiatric management of Huntington's disease in extended care settings. *Psychiatric services (Washington, DC)* 2002; **53**: 703-705.
- Wytenbach A, Carmichael J, Swartz J, Furlong RA, Narain Y, Rankin J et al. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein

aggregation in cellular models of Huntington's disease. *Proc Natl Acad Sci USA* 2000; **97**: 2898-2903.

Y

Yamamoto A, Cremona ML, Rothman JE Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. *J Cell Biol* 2006; **172**: 719-731.

Yamamoto A, Lucas JJ, Hen R Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. *Cell* 2000; **101**: 57-66.

Yang Z, Chang YJ, Yu IC, Yeh S, Wu CC, Miyamoto H et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. *Nat Med* 2007; **13**: 348-353.

Z

Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. *Nat Genet* 1995; **11**: 155-163.

Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. *Nat Genet* 1997; **15**: 62-69.

Zuccato C, Marullo M, Conforti P, MacDonald ME, Tartari M & Cattaneo E. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. *Brain Pathol.* 2008; **18**: 225-238.

Zwickl P, Voges D, Baumeister W The proteasome: a macromolecular assembly designed for controlled proteolysis. *Philos Trans R Soc Lond, B, Biol Sci* 1999; **354**: 1501-1511.